top of page

USFDA Guidance: Psychedelic Drugs-Considerations for Clinical Investigations

Writer's picture: Sharan MuruganSharan Murugan

Recently last week Friday (23 June 2023) the United States Food & Drug Administration's Center for Drug Evaluation and Research released a draft guidance on "Psychedelic Drugs: Considerations for Clinical Investigations".

Psychedelic drugs, also referred to as hallucinogens, are a class of psychoactive substances that can profoundly alter perception, cognition, and consciousness. Hallucinations, enhanced sensory perception, altered thought patterns, and mood changes are among the subjective experiences produced by these substances.


In this guidance, the Food and Drug Administration (FDA) provides general considerations for sponsors developing psychedelics to treat medical conditions (such as psychiatric disorders and substance abuse disorders).


The guidance applies to clinical trials conducted under investigational new drug applications (INDs), including non-marketing clinical trials (e.g., research or academic studies). Its principles aim both to ensure the integrity of clinical trials and their reliability, as well as to support the ethical conduct of trials.


The potency and/or pharmacodynamics of psychedelic drugs should be adequately characterized in vitro and in vivo, as well as the following clinical pharmacology aspects should be considered by sponsors when developing psychedelic drugs.


Click this LINK to know more about what are the Considerations for Clinical Investigations for Psychedelic Drugs.


Also, CBER released another guidance "Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical" which addresses the urgent and immediate need for platelets for the treatment of active bleeding when conventional platelets are not available or are impractical.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page